Form 8-K - Current report:
SEC Accession No. 0001193125-25-140285
Filing Date
2025-06-13
Accepted
2025-06-13 06:05:38
Documents
14
Period of Report
2025-06-13
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d877944d8k.htm   iXBRL 8-K 50907
2 EX-99.1 d877944dex991.htm EX-99.1 33416
6 GRAPHIC g877944g0613073723307.jpg GRAPHIC 2519
  Complete submission text file 0001193125-25-140285.txt   217417

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elvn-20250613.xsd EX-101.SCH 2887
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20250613_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20250613_pre.xml EX-101.PRE 11283
16 EXTRACTED XBRL INSTANCE DOCUMENT d877944d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 251044655
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)